Search
Jianfeng Group Announces Marketing Approval for Vonoprazan Fumarate Chemical API
2025-08-13 /
Read about 0 minute
Author：小编
Anhui Jianfeng Beika Pharmaceutical, a subsidiary of Jianfeng Group, has received notification from the National Medical Products Administration that its chemical API (Active Pharmaceutical Ingredient) for Vonoprazan Fumarate has secured marketing approval. This groundbreaking API is specifically designed to treat reflux esophagitis and falls under the category of potassium-competitive acid blockers.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
